Naveris, Inc., the leader in precision oncology diagnostics for viral-driven cancers, today announced that it will be highlighting new data supporting the use of blood-based ctDNA tests to improve ...

Biomarker testing has become “increasingly critical” in the care of non-small cell lung cancer.A new investigation into testing rates proved “reassuring” to Kenneth L. Kehl, MD, MPH, assistant ...

The firm began a Phase II study of evorpacept in HER2-positive breast cancer patients and began testing a higher dose of ALX2004 in a separate Phase I trial.

In Brazil, the early detection of genetic alterations in lung cancer through liquid biopsies could be a valuable tool for ...

CITCCA study data demonstrate strong association between ctDNA status and recurrence risk in stage I-III colorectal cancerMORRISVILLE, N.C.--(BUSINESS WIRE)--#ASCOGI--SAGA Diagnostics, a pioneer in ...

Ramez N. Eskander, MD, discusses the heterogenous nature of endometrial cancer and molecular testing being used to identify appropriate patients for specific treatments. He also highlights what study ...

VANCOUVER, BC, Dec. 31, 2025 /CNW/ -- The precision oncology market surged to $139.4 billion in 2025 and is racing toward $317.5 billion by 2035([1]) , driven by a fundamental shift in cancer ...

Despite major therapeutic advances, breast cancer remains prone to recurrence, particularly in patients with early-stage ...

This work was supported by the National Natural Science Foundation of China (Grant No. 82373113, XJ), Shenyang Breast Cancer ...

Breast cancer relapse often begins long before it can be seen. Tiny clusters of residual tumor cells may persist after treatment, quietly driving ...

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of a new study in Clinical Cancer Research, a ...

Data include findings generated using the RaDaR 1.0 assay to assess molecular residual disease and recurrence risk in early breast cancer NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of ...